The week in pharma: action, reaction and insight - week to October 29, 2021

31 October 2021

By Barbara Obstoj-Cardwell

Apart from financial results, clinical trial results were much in evidence among the news last week. Novartis’ already-marketed canakinumab missed Phase III clinical goals in lung cancer for a second time. Sanofi and Regeneron released new data on their Dupixent in the treatment of eosinophilic esophagitis along with plans for regulatory filings. Also, there was disappointment in the Alzheimer’s space, when US biotech Cortexyme last Tuesday reported missed endpoints in a Phase II/III of its candidate atuzaginstat. Meantime, the announcement that Alnylam’s long-time chief executive John Maragonore was leaving after 19 years came as a big surprise.

Novartis won’t can canakinumab

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK